Heavey S - Search Results

1

Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC.

Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, Finn SP, O'Byrne KJ, Gately K. Heavey S, et al. Cancer Biol Ther. 2014 Oct;15(10):1367-77. doi: 10.4161/cbt.29841. Epub 2014 Jul 15. Cancer Biol Ther. 2014. PMID: 25025901 Free PMC article.

2

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.

Heavey S, O'Byrne KJ, Gately K. Heavey S, et al. Cancer Treat Rev. 2014 Apr;40(3):445-56. doi: 10.1016/j.ctrv.2013.08.006. Epub 2013 Aug 26. Cancer Treat Rev. 2014. PMID: 24055012 Review.

3

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.

Heavey S, Cuffe S, Finn S, Young V, Ryan R, Nicholson S, Leonard N, McVeigh N, Barr M, O'Byrne K, Gately K. Heavey S, et al. Oncotarget. 2016 Nov 29;7(48):79526-79543. doi: 10.18632/oncotarget.12755. Oncotarget. 2016. PMID: 27765909 Free PMC article.

4

Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines.

Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, Cuffe S, Finn SP, O'Byrne KJ, Gately K. Heavey S, et al. Sci Rep. 2018 Jan 26;8(1):1652. doi: 10.1038/s41598-018-19688-1. Sci Rep. 2018. PMID: 29374181 Free PMC article.

5

Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.

Ryan SL, Beard S, Barr MP, Umezawa K, Heavey S, Godwin P, Gray SG, Cormican D, Finn SP, Gately KA, Davies AM, Thompson EW, Richard DJ, O'Byrne KJ, Adams MN, Baird AM. Ryan SL, et al. Among authors: heavey s. Lung Cancer. 2019 Sep;135:217-227. doi: 10.1016/j.lungcan.2019.07.006. Epub 2019 Jul 12. Lung Cancer. 2019. PMID: 31446998

6

Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC.

Moore G, Lightner C, Elbai S, Brady L, Nicholson S, Ryan R, O'Sullivan KE, O'Byrne KJ, Blanco-Aparicio C, Cuffe S, O'Neill M, Heavey S, Finn SP, Gately K. Moore G, et al. Among authors: heavey s. Cancers (Basel). 2021 Apr 29;13(9):2139. doi: 10.3390/cancers13092139. Cancers (Basel). 2021. PMID: 33946744 Free PMC article.

7

Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer.

Malone T, Schäfer L, Simon N, Heavey S, Cuffe S, Finn S, Moore G, Gately K. Malone T, et al. Among authors: heavey s. Pharmacol Ther. 2020 Mar;207:107454. doi: 10.1016/j.pharmthera.2019.107454. Epub 2019 Dec 11. Pharmacol Ther. 2020. PMID: 31836451 Review.

8

Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.

Luszczak S, Simpson BS, Stopka-Farooqui U, Sathyadevan VK, Echeverria LMC, Kumar C, Costa H, Haider A, Freeman A, Jameson C, Ratynska M, Ben-Salha I, Sridhar A, Shaw G, Kelly JD, Pye H, Gately KA, Whitaker HC, Heavey S. Luszczak S, et al. Among authors: heavey s. Sci Rep. 2020 Sep 1;10(1):14380. doi: 10.1038/s41598-020-71263-9. Sci Rep. 2020. PMID: 32873828 Free PMC article.

9

Targeting nuclear factor-kappa B to overcome resistance to chemotherapy.

Godwin P, Baird AM, Heavey S, Barr MP, O'Byrne KJ, Gately K. Godwin P, et al. Among authors: heavey s. Front Oncol. 2013 May 16;3:120. doi: 10.3389/fonc.2013.00120. eCollection 2013. Front Oncol. 2013. PMID: 23720710 Free PMC article.

10

PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Luszczak S, Kumar C, Sathyadevan VK, Simpson BS, Gately KA, Whitaker HC, Heavey S. Luszczak S, et al. Among authors: heavey s. Signal Transduct Target Ther. 2020 Jan 31;5(1):7. doi: 10.1038/s41392-020-0109-y. Signal Transduct Target Ther. 2020. PMID: 32296034 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

60 results

Search Page